Pfizer Research Technology Center (RTC)
620 Memorial Drive
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
46 articles with Pfizer Inc.
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
U.S. FDA Approves PREVNAR 20 ™ , Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older.
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001) Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2 infection Latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma.
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
U.S. FDA Approves PANZYGA ® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The first and only FDA-approved intravenous immunoglobulin with two maintenance dosing options for CIDP
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO ® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Pfizer Confirms U.S. Patent Term Extension for IBRANCE ® (palbociclib) Until March 2027
Imcyse Enters into Research Collaboration and License Agreement for its Imotope(TM) Technology with Pfizer in Rheumatoid Arthritis
Imcyse and Pfizer to collaborate to develop Imotope TM candidates to potentially treat Rheumatoid Arthritis Pfizer to lead clinical development and commercialization activities
Upjohn Business (1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted (2) Results Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclude Upjohn (1) , Reflect 3% Operational Growth; When the Impact from Consumer Healthcare (1) and the $154 Million of Sales of BNT162b2 are Excluded, Full-Year 2020 Revenues Grew 8% Operationally
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)
Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467).
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39 th Annual J.P. Morgan Healthcare Conference to be held virtually. Albert Bourla, Chairman and Chief Executive Officer, will participate in a fireside chat presentation on Tuesday, January 12, 2021 at 10:00 a.m. EST. Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, wi
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
LORBRENA ® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA Supplemental New Drug Application being reviewed under FDA Real-Time Oncology Review (RTOR) and Project ORBIS pilot programs Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
COMIRNATY ® (also known as BNT162b2) receives conditional marketing authorization from the European Commission; this milestone represents a global joint effort to advance the first authorized mRNA vaccine
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
FDA expected to make a decision on Emergency Use Authorization in the coming days Positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data If authorized, BNT162b2 would be the first COVID-19 vaccine available in the U.S.
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China
Pfizer, Inc. (NYSE: PFE) and LianBio announced today that they have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China. LianBio, founded by Perceptive Advisors, forged a collaboration with Pfizer to pursue an innovative business development opportunity. Both companies will be dedicated to advancing best-in-class therap
Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitu